Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

The findings are published in Science Translational Medicine.

This study was performed in the lab of Baozhong Shen, the TOF-PET/CT/MR Center of The Fourth Hospital of Harbin Medical University and the Molecular Imaging Research Center (MIRC) of Harbin Medical University.

The senior authors are Dr. Baozhong Shen, Harbin Medical University Professor of Radiology, Dr. Sanjiv Sam Gambhir, Professor & Chair of Radiology, Stanford University, School of Medicine and Dr. Zhen Cheng, Associate Professor of Radiology, Stanford University, School of Medicine.

Dr. Xilin Sun, Harbin Medical University Professor of Radiology, is the lead author. Drs. Baozhong Shen and Xilin Sun are scientists at the Molecular Imaging Research Center (MIRC) of Harbin Medical University.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

While several techniques are currently available to assess EGFR mutation status, these methods require tumour biopsies and can often fail or have poor reproducibility due to insufficient material for mutation analysis.

Additionally, intra- and inter-tumour heterogeneity over space and time makes it even more challenging to assess EGFR mutation status in real time.

Plasma samples of patients with NSCLC is a less invasive method and has been used as surrogate tumour tissues for detecting genetic alterations.

However, many studies have found the inconsistency of EGFR mutation status in plasma DNA samples as compared to tumour tissue DNA samples.

Plasma samples also cannot address the issue of expression heterogeneity (primary tumour vs. metastatic site(s)).

"How can we overcome the limitations of tumour tissue biopsy and plasma samples for detecting genetic alterations, and obtain comprehensive tumour EGFR profiling in real-time?" asked Dr. Baozhong Shen. "Can this technique provide both EGFR mutation status information at the molecular level and precise anatomical information such as size, shape, NSCLC tumour location(s), and their relationship with adjacent structures?".

"Molecular imaging with PET shows the potential for non-invasively detecting cancer biomarkers in primary or metastatic tumours, and therefore for identifying patients who are likely to respond to specific treatments." Shen said. "We wanted to develop a novel strategy with PET imaging for non-invasively determining EGFR mutation status in real-time, predict NSCLC patients who may benefit from EGFR-TKI therapy, and monitor EGFR-TKI treatment outcome".

The researchers designed and synthesized a novel small molecule PET tracer, 18F-MPG, with high specificity to activating EGFR mutant kinase.

The preclinical studies showed that the newly developed 18F-MPG allows one to noninvasive and repeatedly detect activating EGFR mutational status in mouse models of NSCLC with high sensitivity and specificity.

More importantly, the researchers then translated this strategy to NSCLC patients. The first-in-human PET/CT imaging of 75 patients with 18F-MPG was performed to show that this tracer can be used as a companion diagnostic to identify NSCLC patients with EGFR activating mutant tumours (primary tumour or metastatic) with 84.3% accuracy.

Good patient outcomes were observed after EGFR-TKI therapy in the subpopulation with very high pretreatment 18F-MPG uptake, which demonstrates the potential of using 18F-MPG PET/CT to predict treatment response.

These results demonstrate that noninvasive imaging of EGFR activating mutation status in primary and metastatic tumours with 18F-MPG PET/CT is a valid strategy for stratifying NSCLC patients for EGFR-TKI treatment.

This strategy achieves: (i) differentiating of tumour EGFR-activating mutation status with non-invasive, whole-body PET imaging; (ii) prediction of EGFR-TKIs sensitivity/resistance and patient survival; and (iii) monitoring of the dynamic changes in EGFR mutation status during therapy and guidance of precise treatment.

"There currently are no methods to predict EGFR-TKI therapy response in patients and design effective EGFR-TKIs therapies when a genetic test is not feasible or ambiguous." Shen said. "With 18F-MPG PET/CT imaging, we were able to quantitate EGFR-activating mutation status in NSCLC patients (primary tumour or metastatic) and directly determine/visualize the location(s) and morphology of the NSCLCs."

This new study is believed to be the first reported to analyze the association between EGFR mutation status in tumour tissue and 18F labelled EGFR-TKI tracer uptake in NSCLC patients.

Source: MIRC